MedTrace Logo

Impact of Omega 3 Fatty Acid Supplementation on Aromatase in Obese Subjects

NCT02538484 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2023-07-17

No results posted yet for this study

Summary

Assess the impact of dietary omega 3 free fatty acids and/or letrozole on obese, postmenopausal breast cancer patients.

Conditions

Interventions

DRUG

Letrozole

Aromatase inhibitor

DIETARY_SUPPLEMENT

Fish Oil

Omega-3 free fatty acid

Sponsors & Collaborators

  • The University of Texas Health Science Center at San Antonio

    lead OTHER

Principal Investigators

  • Andrew Brenner, MD, PhD · Principal Investigator

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-04-30
Primary Completion
2020-03-11
Completion
2020-03-26

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02538484 on ClinicalTrials.gov